Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells by Lohr, V. et al.
Lohr et al. BMC Biotechnology 2012, 12:79
http://www.biomedcentral.com/1472-6750/12/79RESEARCH ARTICLE Open AccessLive attenuated influenza viruses produced in a
suspension process with avian AGE1.CR.pIX cells
Verena Lohr1*, Yvonne Genzel1, Ingo Jordan2, Dietmar Katinger3, Stefan Mahr1,4, Volker Sandig2 and Udo Reichl1,5Abstract
Background: Current influenza vaccines are trivalent or quadrivalent inactivated split or subunit vaccines
administered intramuscularly, or live attenuated influenza vaccines (LAIV) adapted to replicate at temperatures
below body temperature and administered intranasally. Both vaccines are considered safe and efficient, but due to
differences in specific properties may complement each other to ensure reliable vaccine coverage. By now, licensed
LAIV are produced in embryonated chicken eggs. In the near future influenza vaccines for human use will also be
available from adherent MDCK or Vero cell cultures, but a scalable suspension process may facilitate production and
supply with vaccines.
Results: We evaluated the production of cold-adapted human influenza virus strains in the duck suspension
cell line AGE1.CR.pIX using a chemically-defined medium. One cold-adapted A (H1N1) and one cold-adapted
B virus strain was tested, as well as the reference strain A/PR/8/34 (H1N1). It is shown that a medium
exchange is not required for infection and that maximum virus titers are obtained for 1 × 10-6 trypsin units
per cell. 1 L bioreactor cultivations showed that 4 × 106 cells/mL can be infected without a cell density effect
achieving titers of 1 × 108 virions/mL after 24 h.
Conclusions: Overall, this study demonstrates that AGE1.CR.pIX cells support replication of LAIV strains in a
chemically-defined medium using a simple process without medium exchanges. Moreover, the process is fast
with peak titers obtained 24 h post infection and easily scalable to industrial volumes as neither microcarriers
nor medium replacements are required.
Keywords: Live attenuated influenza virus, Influenza vaccine production, Suspension cell culture, Cell density
effect, AGE1.CR.pIXBackground
Annual vaccination is the most efficient way to reduce the
immense number of 3–5 million cases of severe illness or
death due to influenza virus infections. Different vaccine
types have been developed and are being deployed for this
purpose over the past 60–70 years. The most common
type is the trivalent influenza vaccine (TIV) derived from
inactivated whole virus. TIVs are injected intramuscularly
or intradermal. They have a favorable safety profile
and induce reliable protective immunity against viral
strains which are similar to those present in the vaccine.
However, because efficacy against new virus variants can
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reproduction in any medium, provided the orpredicted for each influenza season [1]. Another type of
influenza vaccines is the live attenuated influenza vaccine
(LAIV) comprising virus strains that are adapted to
replication at temperatures below the human body
temperature. LAIVs are administered through a nasal
spray mimicking a natural infection of the mucosal
cells of the nasopharynx. However, these viruses cannot
replicate at non-permissive temperatures present in the
lower respiratory tract and lungs. Due to the attenuated
infection in the upper respiratory tract, these vaccines
induce not only strain specific immunity but also T cell
responses that may be cross-reactive and thus contribute
to protection against a wider spectrum of influenza A and
B strains [2-4]. The only approved LAIVs are FluMistW
(MedImmune) for the US and Russian market and, since
2011, the European analogue FluenzW, both produced in an
egg-based process [5]. As opposed to parenteral inactivatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stringent and thus less expensive for mucosal live virus
vaccines. Also for this reason, the WHO encouraged to
extend the manufacturing of LAIVs as part of the global
pandemic influenza action plan [6].
Production of LAIVs has so far been investigated in
three host systems: chicken eggs [7], adherent MDCK
[8-10] or adherent Vero cells [11-13]. Because properties
such as replication kinetics, viral RNA synthesis and
protein expression appear to be comparable in cell
culture- or egg-derived virus strains [14], both have been
approved for the production of vaccines for human use.
However, there are inherent limitations associated with
the process design related to the decision for a specific
host system, being more or less pronounced for one or
the other. Scalability, for example, is impaired signifi-
cantly for adherent cell lines cultivated in static or
microcarrier systems. The use of suspension-adapted cell
lines such as MDCK and Vero could overcome this
limitation. These cells have been adapted to growth
in suspension by several groups [15-18] and by the
industry where they are already used in vaccine
manufacturing [19]. Other suspension cell lines use-
ful for influenza vaccine production are PER.C6 [20],
HEK293 [21], EB66 [22] or AGE1.CR.pIX (in the following:
CR.pIX) [23,24].
The CR.pIX cell line has been generated specifically for
production of modern vaccines. Its derivation and identity
is fully documented and genetic stability was shown for at
least 90 passages [25]. As required by regulatory authorities,
the absence of adventitious agents was confirmed via
extensive testing of CR.pIX cell banks by a spectrum
of methods such as transmission electron microscopy
against microbial structures; diagnostic PCR reactions
against specific avian, bovine and porcine agents; in vitro
assays with various sentinel cell lines for any cytopathic
effects; in vivo assays in different animal species for any
signs of infection or induction of antibodies; quantita-
tive fluorescent product enhanced reverse transcriptase
(QFPERT) assay and co-cultivation to detect endogenous
or exogenous retroviral contamination; and inoculation of
cell line material into various agars and broths to test
against mycoplasma and other bacteria. With regards to
process technology, this cell line proliferates in suspension
in a chemically-defined medium and has been shown to
support influenza A virus replication. Moreover, CR.pIX
cells are expected to be susceptible for a broad spectrum of
virus subtypes and strains as they display both α2,3- and
α2,6-linked sialic acids as surface membrane receptors [26].
For the design of vaccine production processes using a
new host cell, studies concerning crucial infection para-
meters like trypsin activity and multiplicity of infection
(moi) are necessary. In addition, the cell concentration at
time of infection (CCI) has been reported to be importantfor adenovirus, baculovirus and influenza virus production
[21,27-30]. These studies demonstrated that above a
certain CCI, the cell-specific virus productivity drops
substantially, what is called the “cell density effect”.
All studies related to this topic indicate that the rea-
sons for the cell density effect are highly dependent
on the production system (mainly virus species, host
cell line and medium) and thus cannot be generalized.
Explanations for this effect include depletion of
nutrients or accumulation of inhibiting substances
[30]. Also, activity or availability of host cell factors
required for virus replication may change with the
cell cycle [31] or with metabolic shifts [28,31] at
higher cell densities. As an example, for production
of influenza virus typically 1-2 × 106 cells/mL are
used, but with fed-batch or perfusion strategies ex-
haustion of medium components and influence of
inhibiting substances can be avoided and high-yield
infections of 1 × 107 cells/mL have been demon-
strated [32,33]. The aim of overcoming the cell
density effect is to maintain or even increase the
cell-specific productivity in order to improve process
productivity, i.e. to increase the vaccine doses which
can be harvested per reactor volume.
In this work, we produced human LAIV strains in a
chemically-defined medium using CR.pIX cells. One
cold-adapted (ca) influenza A strain (H1N1), one ca
influenza B strain as well as the reference strain A/PR/8/34
(H1N1; not cold-adapted) were propagated. After adapting
the virus strains to CR.pIX cells we confirmed temperature
sensitivity and identified best cultivation conditions such as
medium supply and trypsin activity for successful infec-
tion in small-scale scouting experiments. Subsequently,
batch bioreactor cultivations were performed to dem-
onstrate that cultures can be productively infected at a
CCI of 4 × 106 cells/mL without any medium exchange,
doubling the CCI that has been used previously with
CR.pIX cells (2 × 106 cells/mL) [23]. Only at higher CCI
a cell density effect was observed when infecting with-
out a medium exchange. In all experiments, high titers
and fast replication dynamics have been achieved dem-
onstrating a chemically-defined suspension production
process for influenza LAIV strains.
Results
The chemically-defined medium CD-U2 supports direct
infection
Experimental data on influenza virus production in CR.pIX
cells is available only for cultures in serum-free proliferation
medium containing hydrolysates [23]. However, to improve
proliferation of CR.pIX cells and to reduce risk of lot-to-lot
inconsistencies due to variable hydrolysate composition, a
chemically-defined medium (CD-U2) has been developed
specifically for this cell line [25]. As a reference for the
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virus stability and the requirement for a medium exchange,
replication of the human influenza virus strain H1N1
A/PR/8/34 was investigated first. This strain is included
regularly in similar studies and titers obtained with CR.
pIX cells therefore can be compared to other producer
cells.
CR.pIX cells were infected with A/PR/8/34 without
medium exchange, after a partial medium exchange
(half of the culture), or after a complete medium ex-
change. Infection took place at a CCI of 2 × 106 cells/mL
that was reached approximately two days after culture
inoculation.
HA yields and TCID50 titers differed slightly using
the three medium exchange strategies (Figure 1) with
a trend towards lower titers when a medium exchange
was applied. The HA yield reached a plateau of 2.0-2.3
log10 HA units/100 μL at 24 h post infection (hpi) and
remained stable until 72 hpi (later data points not
shown). TCID50 titers reached a maximum at 24 hpi,
but were less stable than the HA yield, decreasing about
1 log unit in 48 h. The maximum TCID50 of 1.3 × 10
8
virions/mL was obtained in cultures which have been
infected directly and lowest TCID50 was observed after
exchanging half of the growth medium. None of the
cultures exhibited limiting substrate levels at time of
infection, which was confirmed with metabolite con-
centration measurements (data not shown). From these
results we concluded that a medium exchange is not
required and that CD-U2 supports stable HA virus yields
and good TCID50 titers at a CCI of 2 × 10
















Figure 1 TCID50 titers (open symbols) and HA yields (closed symbols)
strategies. CR.pIX cells were infected with influenza strain A/PR/8/34 in sh
cell. Three strategies were performed: infection without medium exchange
of 50% of the medium (●, purple). Error bars indicate standard deviation ofTemperature sensitivity of LAIV strains is maintained after
adaptation
Influenza virus has a broad host range and can shuttle
between mammalian and avian cells. However, virus repli-
cation dynamics and maximum titers may be impaired by a
sudden shift to a new cell substrate and may be improved
by serial passages of the virus in the new host cell line. For
this reason, the LAIV strains A/Singapore and B/Vi-
enna (for details on these strains see materials & meth-
ods section) were adapted to CR.pIX cells to generate
working seed viruses with high titers. At the same time,
care was taken to achieve this with a minimum number of
passages (maximum 3) to minimize the potential for
reversion to replication at non-permissive temperatures.
After adaptation to CR.pIX cells, the A/Singapore and
B/Vienna strain had, respectively, 1.1 and 1.4 log10
increased maximum TCID50 titers. The chosen seed
viruses were from passage 3 for the A/Singapore strain,
harvested at 28 hpi, and from passage 2 for the B/Vienna
strain, harvested at 34 hpi. Overall, 5 (A/Singapore)
and 6 days (B/Vienna) were needed to complete the adap-
tation to CR.pIX cells. The mentioned harvests were used
as working seed viruses for all subsequent experiments.
Considering temperature sensitivity, we tested replication
of both ca strains at 37°C before adaptation to CR.pIX cells
and could not detect any virus titer, whereas virus propaga-
tion was successful at 33°C (Table 1). To test whether the
required temperature sensitivity of LAIV strains was still
present after the adaptation process, infection experiments
were conducted at 33, 37 and 40°C. The B strain was highly



















from infections performed with different medium exchange
aker flasks at a CCI of 2 × 106 cells/mL and 1 × 10-6 units trypsin per
(■, black), after a medium exchange (▲, cyan) and after the exchange
three independent cultures.
Table 1 Temperature sensitivity of A/Singapore and B/
Vienna viruses in CR.pIX cells
Maximum TCID50 titers [virions/mL]
* 33°C 37°C 40°C
Before adaptation to CR.pIX cells
A/Singapore 1.3 × 108 0 -#
B/Vienna 1.8 × 105 0 -
After adaptation to CR.pIX cells
A/Singapore 2.4 × 108 1.8 × 106 0
B/Vienna 3.2 × 106 0 -
*Maximum titers of CR.pIX cells infected in T-flasks at a CCI of 2 × 106 cells/mL
and with 1 × 10-6 units trypsin per cell.
#not determined.
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replication at 40°C. The A/Singapore strain produced about
40 times less active virus particles at 37°C compared to
33°C. At 40°C, no active particles were detected. These
results indicate that both working virus seeds exhibit the
expected temperature sensitivity.Optimization of trypsin activity
LAIV strains replicate at 33°C and the activity of trypsin
(initially optimized for replication at 37°C) is expected to
be slightly reduced at 33°C [34]. To test whether this
reduction requires higher amounts of trypsin for propa-
gation of cold-adapted virus strains, we tested different
trypsin activities with A/Singapore and B/Vienna (Figure 2).
When using 1 × 10-6 units/cell (standard concentration for
A/PR/8/34 propagation), maximum TCID50 values were
measured at 48 hpi. An increase of the trypsin activity to
5 × 10-6 units/cell or even 10 × 10-6 units/cell reduced the
titers of A/Singapore and B/Vienna. Infections without
trypsin addition did not produce any infectious virus
particles. Thus, without further adaptation of thisFigure 2 Optimization of trypsin activity used for the infection of CR.
Tested trypsin activities were 1 × 10-6 units/cell (green), 5 × 10-6 units/cell (o
a CCI of 2 × 106 cells/mL without applying a medium exchange.parameter, 1 × 10-6 units trypsin per cell was found to
support best the replication of A/Singapore (2.4 × 108
virions/mL) and B/Vienna (3.2 × 106 virions/mL).Cell density effect in bioreactor cultivations
Whether the ca strains can be produced in bioreactors is
an important test towards suitability of LAIV strain produc-
tion for seasonal or pandemic vaccines in the CR.pIX
suspension cells. Focusing on the A/Singapore strain, we
therefore performed experiments in a benchtop stirred tank
bioreactor system to test the scale-up potential. The cell
density effect was evaluated by varying the cell concentra-
tion at time of infection with the aim to identify the highest
CCI that can be used without reduction of cell-specific
productivity. One problem for infection at high CCI could
be the release and accumulation of trypsin inhibitors during
the growth phase. We therefore also tested if a higher
trypsin activity or a medium feed at high CCI can
rescue productivity. Six bioreactor runs were performed
with infections at 4 × 106 cells/mL (three days batch
growth), 6 × 106 cells/mL (five days batch growth) and 8 ×
106 cells/mL (six days batch growth) (Figure 3A). Exact
cell concentrations together with added trypsin and
medium are summarized in Table 2.
At the lowest CCI (4 × 106 cells/mL), cell-specific virus
yields of 15 (CCI_4_1) and 19 active virions/cell (CCI_4_2)
were obtained. Infection of the intermediate group with a
CCI of about 6 × 106 cells/mL led to reduced titers
(1 × 107 virions/mL for both cultures) compared to
the lowest CCI (1 × 108 virions/mL) and, correspond-
ingly, reduced cell-specific productivities (1–2 virions/
cell). Using a high CCI of about 8 × 106 cells/mL
resulted in titers of 8 × 106 virions/mL and 6 × 107 vir-
ions/mL, respectively, and hence also low cell-specific viruspIX cells with LAIV strains A/Singapore (A) and B/Vienna (B).
range) and 10 × 10-6 units/cell (black). Cells were infected in T-flasks at
CB
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A
Figure 3 Infection of CR.pIX cells with the LAIV strain A/Singapore at different cell concentrations at time of infection. Viable cell
concentrations (A), viabilities (B) and TCID50 titers (C) of bioreactor cultivations are shown. Cells were infected with parameters summarized in
Table 2: CCI_4_1 (■, black) and CCI_4_2 (□, black), CCI_6_1 (●, green) and CCI_6_2 (○, green), CCI_8_1 (▼, orange) and CCI_8_2 (∇, orange).
After the cell growth phase at 37°C, bioreactor temperature was controlled at 33°C during the infection phase. Error bars for viable cell
concentrations and viabilities indicate standard deviations of triplicate measurements.
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neither the titer nor the productivity was rescued when
applying a higher trypsin activity (10 × 10-6 units/cell) or a
medium addition (200 mL) at the highest CCI. For all
cultures, viability at time of infection was above 90%
(Figure 3B), showing that cells were not impaired due to
extension of the growth phase. Thus, a cell density effect,
i.e. a loss in cell-specific virus productivity, was observed
at CCI above 4 × 106 cells/mL.Table 2 Bioreactor cultivations performed with the LAIV strai
CCI_4_1 CCI_4_2
CCI [viable cells/mL] 4.2 × 106 4.1 × 106
Trypsin conc. [units/cell] 10 × 10-6 1 × 10-6
Feed - -
CR.pIX cell cultures were infected at different CCI and trypsin activities. Upon infectA comparison to shaker flask experiments (which
resulted in 15–20 virions/cell, data not shown) con-
firmed that scale-up to a benchtop bioreactor did
not reduce virus titers or productivities at a CCI of
4 × 106 cells/mL. From these results we conclude
that a CCI of up to 4 × 106 cells/mL can be used for
virus production without the requirement for a
medium exchange and, most importantly, without
loss of cell-specific productivity.n A/Singapore
CCI_6_1 CCI_6_2 CCI_8_1 CCI_8_2
6.5 × 106 6.1 × 106 7.4 × 106 8.0 × 106
1 × 10-6 1 × 10-6 10 × 10-6 10 × 10-6
- - - 200 mL
ion, the temperature was reduced to 33°C for virus propagation.
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Increasing and unmet demand for vaccination against sea-
sonal and pandemic influenza virus is a strong motivation
for exploring additional means in vaccine manufacturing.
Currently, most inactivated and the live attenuated
influenza vaccines are manufactured in embryonated
chicken eggs, an established technology but associated
with demanding logistics, risks of allergic reactions and
difficulties in scalability. Therefore, some influenza
vaccine manufacturers have developed new produc-
tion processes for influenza vaccines in cell culture
(Vero and MDCK cells), although LAIVs are still ex-
clusively produced in eggs [35]. In particular, the use
of continuous cell lines adapted to growth in suspen-
sion has the potential for large scale production in
closed systems using a comparatively simple generic
process. We therefore investigated replication of influenza
virus in the CR.pIX cell line, which is specifically created
and designed for vaccine manufacture and is adapted to
proliferate in chemically-defined media. Generally, CR.
pIX cells show a good proliferation performance with
growth rates in the range of 0.016 and 0.023 h-1
(derived from the exponential growth phase of the
bioreactor cultivations shown in Figure 3). After
seven days, approximately 1 × 107 cells/mL can be
achieved in batch cultivation. In conjunction with a
well-balanced medium (CD-U2), this leads to a short
growth phase so that infections can be initiated soon
after inoculation.
In the first part of our study we demonstrate that CR.
pIX cells can produce influenza virus to high titers in
shaker flasks. For the reference strain A/PR/8/34, TCID50
titers of 1.3 × 108 virions/mL were achieved, which is in a
similar range (107 to 109 virions/mL) reported for other
cell lines [19,35,36]. The achieved HA titers (used to
calculate the number of vaccine doses for inactivated
virus vaccines) are about 2.0 log HA units/100 μL
which is slightly lower than those normally obtained
with conventional cells (MDCK or Vero cells) or new
candidate cell lines (HEK293, PER.C6). Mostly, these
are reported to propagate the A/PR/8/34 influenza virus
strain to titers of 3.0 to 3.6 log HA units/100 μL
[21,35-37]. Generally, CR.pIX cells seem to generate
the same TCID50 titers, but slightly lower HA titers
and thus should in particular be considered for the produc-
tion of LAIV strains. With a medium replacement at time
of infection, we could not observe a titer increase and thus
we conclude that a process without any medium exchange
is possible in this system, a property which substantially
simplifies a suspension process at industrial scales.
LAIV strains must have a temperature-sensitive and
cold-adapted phenotype in order to be considered safe for
use in human vaccination. Thus, we tested temperature
sensitivity after adapting the ca strains to CR.pIX cells.The B/Vienna strain showed to be temperature-sensitive
as no active virions were produced at 37°C. The titer of
A/Singapore was reduced about 1.5 log at 37°C com-
pared to 33°C (40%). This reduction is not as clear as
for the B strain but expected from previous studies as
the replication deficiency must be obvious only at 39 or
40°C for A strains [38]. Other studies have demon-
strated a titer reduction of 20% at 37°C compared to
the titer at 33°C [39] and of 2 log units for the master
donor strain B/AnnArbor/1/66 strain [40]. This range
was also observed here. Testing the temperature sensitivity
before and after adaptation to CR.pIX cells (restricted to 2–
3 passages) confirmed the temperature-sensitive phenotype.
Both ca strains were pheno- and genotypically character-
ized for patent registration before reassortment and adapta-
tion to CR.pIX cells [41], and it was shown that both
cold-adapted strains carry several mutations compared
to the wild type strains. For the A/Singapore strain
there were 13 mutations with 8 of them coding for an
amino acid exchange. For the B/Vienna strain 5 muta-
tions were detected by sequencing with 3 of them
coding for an amino acid exchange. Generally, sequen-
cing of both strains could be of interest for follow-up
studies considering mutations that occur during adap-
tation to the host cell line CR.pIX and considering the
presence of mutations that might be connected with
the temperature-sensitive phenotype [40,42,43].
It is known that for optimal influenza virus replication
trypsin addition is crucial. The selection of the trypsin
activity depends on the cell line (depending on proteases
that are secreted), the medium (protein content), and
also the virus strain [44]. Here, for both LAIV strains we
tested 3 different concentrations to identify an optimal
trypsin activity and found 1 × 10-6 units/cell to result in
highest titers. The reduced temperature of 33°C did not
have an effect on the optimal trypsin concentration
due to an only slightly impaired enzyme activity at
this temperature [34]. However, a design of experiment
approach considering trypsin activity and other parameters
would be useful for further process optimization [17].
Shaker flask experiments were found to be highly
predictive and scale-up to stirred tank bioreactors
was possible without further optimization and with-
out loss of productivity. Particularly this easy scale-
up provides higher flexibility compared to eggs or
adherent cells.
A cell density effect, i.e. reduced titers and productivities
at high CCI, as described for HEK293 cells and insect Sf9
cells infected with adenovirus, influenza virus and
baculovirus [21,27,29,30,45], was also observed with in-
fluenza virus-infected CR.pIX cells. At CCI above a
critical concentration of 4 × 106 cells/mL, cell-specific
virus productivity decreased. The same critical cell con-
centration (4 × 106 cells/mL) was also found in studies
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virus replication is known to modulate the cell cycle to
include the cellular environment for replication [46].
We have observed previously that the cell cycle fractions of
a CR.pIX population at 8 × 106 cells/mL (six days growth)
do not differ significantly from the fractions at 2 × 106 cells/
mL, which corresponds to about three days growth (data
not shown). For this reason, we focused on medium limita-
tions as a cause for the cell density effect. Addition of a 10-
fold higher trypsin activity suggests that impaired
virus propagation was not due to trypsin inhibitors
released by the cells during the growth phase. Fur-
thermore, the depletion of a common medium com-
ponent also appears unlikely as a medium feed could
not rescue virus titers or cell-specific productivities.
Supporting this observation, neither the concentra-
tions of the tested amino acids nor metabolites such
as glucose or pyruvate appeared to be limiting (data
not shown). Still, we cannot rule out that the accu-
mulation of more elusive medium compounds (for ex-
ample lipids, trace elements or vitamins) may be
responsible. Thus, at this moment we speculate that
accumulation of inhibiting substances (that we did
not measure) may cause the cell density effect. This hy-
pothesis is currently tested in perfusion cultivations
where cells are infected at very high cell concentrations.
Future studies will also investigate modification of the
medium (which was designed for proliferation and com-
patibility with a biphasic poxvirus production process
[25]) to increase not only virus titers and productivity
but also the critical CCI.
Our results show that the ca strain A/Singapore
can replicate to 1 × 108 virions/mL in a CR.pIX cell-
based process. This corresponds to approximately
10000 vaccine doses per liter reactor volume assuming
that one dose contains 107 active virus particles (not tak-
ing into account losses during downstream proces-
sing). Romanova et al. obtained 2 × 108 pfu/mL with
the same master donor strain (A/Singapore/1/57 ca) using
adherent Vero cells [11]. With adherent MDCK cells,
titers for the related strain A/NewCaledonia/20/99 of up
to 109 FFU/mL have been reported [8,10,14,47]. Several
influenza B strains were also tested in those studies and
were produced to titers of 108 to 109 virions/mL. As
it is generally known that achievable titers are strain-
specific, extensive optimizations normally help to
maximize titers for each strain. Aggarwal et al. and
George et al. have shown in their studies that high titers for
B strains can be achieved after extensive optimization of
moi, microcarrier concentration, agitation rate and CCI
[10,47]. Thus, we are confident that additional optimization
of CR.pIX cell-based processes (i.e. media and moi
optimization) can further improve the propagation of the
tested B/Vienna strain.Conclusions
Our study provides preliminary evidence for the poten-
tial for production of LAIV to high titers in a suspension
process with an avian cell line. This process is fast with
peak titers already 24 h post infection and easily scalable
to industrial volumes as neither addition of microcar-
riers nor medium replacements are required. The use of
an avian cell line designed specifically for vaccine
production and a chemically-defined medium should
facilitate regulatory approval. Optimization of medium,
feeding or perfusion strategy and process parameters will
be pursued to achieve a further increase in CCI and im-
provement of virus titers.
Methods
Cells
Suspension CR.pIX cells were routinely cultivated in
150 or 250 mL vented and baffled shaker flasks
(working volume 50 or 150 mL, Corning) at 185 rpm
and 5 cm amplitude or in T175 flasks (working volume
50 mL, Greiner) without agitation. Cultivation condi-
tions were 37°C and 5% CO2 in chemically-defined
medium (CD-U2, PAA) supplemented with glutamine,
alanine (both 2 mM final concentration, Sigma) and
recombinant insulin-like growth factor (LONG-R3 IGF,
10 ng/mL final concentration, Sigma). Cells were passaged
twice a week by dilution with fresh medium.
Virus strains
Wild type human influenza virus strain H1N1 A/PR/8/34
was received from the Robert Koch Institute (ampoule
#3138) and adapted to growth in MDCK cells. Cold-
adapted (ca) influenza virus strains were derived by cold-
adaptation of master donor strains, reassortment with
wild-type strains and subsequent adaptation to Vero cell
cultures. These steps were done at Polymun Scientific
GmbH according to Romanova et al. [11]. One A and
one B strain of these Vero-adapted live attenuated
viruses was used in the studies described here: human
influenza H1N1 A/Singapore/1/57 ca × A/Singapore/
2339/2000 (abbreviated as A/Singapore) and human
influenza B/Vienna/1/1999/37 ca × B/Singapore/548/
2000 (B/Vienna).
Analytical methods
Cell concentration and viability were determined with a
ViCELL XR device (BeckmanCoulter). Infectious titers
(TCID50) were measured by titration of supernatants on
MDCK monolayers. Samples from A/PR/8/34 experi-
ments were analyzed at 37°C, whereas samples from
LAIV strains were analyzed at 33°C. Antibodies against
the HA protein were purchased from NIBSC institute,
namely anti-A/PR/8/34 (NIBSC code #03/242), anti-
A/Brisbane/59/2007 (NIBSC code #08/112) for detection
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(NIBSC code #92/582) for detection of the B/Vienna
strain. All primary antibodies were used in a 1:200 dilution.
As a secondary antibody we used donkey anti-sheep
Alexa488 IgG (Invitrogen) in a 1:500 dilution. TCID50 titers
(read-out: virions/mL) were calculated according to
Spearman and Kärber [48]. Cell-specific virus yield
was calculated by dividing the maximal infectious titers
(from TCID50 assay) by the maximal viable cell concen-
tration at or after time of infection. Samples from
A/PR/8/34 experiments were additionally quantified
by hemagglutination (HA) assay [49].
Adaptation of virus strains to CR.pIX cells
CR.pIX-adapted working virus seeds were produced
by passaging the Vero-adapted virus strains in T-flask
cultures of CR.pIX cells (CCI 2 × 106 cells/mL) using
a moi of 10-3. Harvests from several passages and time
points were titrated and harvests with highest titers were
chosen retroactively as seed virus. Adaptation of the ca
strains was done at a reduced temperature of 33°C. CR.
pIX-adapted working virus seeds were stored in aliquots
at −80°C for all further experiments.
Small-scale infection experiments
After inoculating 8 × 105 cells/mL, the cells were grown in
shaker or T175 flasks up to 2 × 106 cells/mL or highercell
concentrations as indicated for the respective experiment.
Calculated volumes of virus seed (for moi 10-3) and trypsin
stock solution (500 units/mL) for the desired trypsin activ-
ity (as indicated for each experiment) were added directly
to the cell suspension. In experiments where a complete
medium exchange was performed, the whole culture was
centrifuged at 150 × g for 10 min to collect cells
prior to re-suspension in fresh medium. For a partial
medium exchange, only half of the culture volume
was centrifuged, re-suspended in fresh medium and
subsequently pooled with the remaining non-centrifuged
culture. Cultures were sampled once or twice per day. Cell
concentration and viability were measured immediately;
all samples for determination of virus titers (TCID50 and
HA yields) were stored at −80°C until analysis of all sam-
ples belonging to the same experiment.
Bioreactor infection experiments
Stirred tank bioreactors (1L working volume, DasGip AG)
were inoculated with 8 × 105 cells/mL. Monitoring and
control of cultivations parameters were carried out with
the cellferm-proW system (DasGip AG). Bioreactors were
equipped with pitched-blade stirrers operated at 120 rpm.
The pO2 was set to 50% by pulsed aeration with air
enriched with variable content of O2 and CO2. The pH
value was allowed to drop from 7.4 to 7.0 during the first
72 h of cell growth and controlled at pH 7.0 afterwards.Analogous to infection optimization at small scale, cells
were grown to the required cell concentration and subse-
quently infected by adding calculated volumes of A/Singa-
pore virus (for moi 10-3) and a trypsin stock solution (5000
units/mL). Upon infection, cultivation temperature was
reduced from 37°C to 33°C. All measurements were per-
formed as described before.
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